Answers are grounded in this paper and cite their sources.
There are species differences regarding the developmental toxicity of procymidone (Sumilex®), a fungicide with a weak anti-androgenic activity. To clarify key factors of these species differences, pharmacokinetic and excretion studies in rats, rabbits, and monkeys were conducted using 14C-labeled procymidone. One hydroxylated metabolite of procymidone (Hydroxylated-PCM: very weak anti-androgen) was found to exist longer and at a much higher concentration in rat plasma than in rabbit and monkey plasma. In rabbits and monkeys, Hydroxylated-PCM was transformed into a glucuronic acid conjugate (Hydroxylated-PCM-glucuronide: non-anti-androgen) and rapidly excreted into urine as a major metabolite. On the other hand, it was a minor metabolite in rat urine. The results of biliary excretion studies indicated that these species differences were caused by the species differences in the biliary excretion of Hydroxylated-PCM-glucuronide; this variation in biliary excretion rate was concluded to be related to species differences in developmental toxicity.
No takes yet. Share an insight, caveat, or question.
Tomigahara et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: